Bedrijfsoverzicht
Scinai Immunotherapeutics Ltd. is a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of biological products designed to treat inflammation and immunology-related conditions, specifically targeting infectious and autoimmune diseases within Israel. The company operates within the broader healthcare sector, specifically classified under the biotechnology industry, a field characterized by high R&D expenditures and significant regulatory hurdles that define its operational landscape. In terms of scale, the organization holds a market capitalization of $2.05M and reported annual revenue of $1.31M for the trailing twelve months, while specific employee count data is not publicly disclosed in the current dataset. These financial figures indicate that Scinai is a micro-cap entity with limited revenue generation relative to its sector peers, suggesting an early-stage operational posture where capital allocation is heavily weighted toward product development rather than widespread commercial expansion or market dominance.
Financiële gezondheid
The company reported revenue of $1.31M over the trailing twelve months, yet it posted a net income loss of $8,307,000 and an EBITDA deficit of $6,121,000, revealing a substantial gap between top-line sales and bottom-line profitability driven by intense operating costs. This disparity highlights a cost structure where research and development expenses significantly outweigh current revenue streams, a common characteristic in biotechnology firms prior to commercializing their primary assets. Free cash flow stands at $-3,329,125, indicating that the company is currently burning cash to fund its operations and innovation pipeline, which limits immediate financial flexibility and reliance on external financing. Analyzing the margin profile, the gross margin is negative at -202.3%, reflecting costs of goods sold that exceed the $1.31M in revenue, while the operating margin of -702.4% and profit margin of 0.0% further illustrate the severe leverage of overhead and R&D costs against sales. Regarding balance sheet strength, the company holds $1.66M in cash against $2.27M in total debt, resulting in a debt-to-equity ratio of 27.98, which suggests a leveraged position where liabilities exceed equity assets. Liquidity is assessed via a current ratio of 1.30, indicating that current assets are sufficient to cover short-term obligations, though the margin is not particularly robust given the cash burn rate. Return on equity is calculated at -91.9% and return on assets at -37.6%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or the asset base, consistent with a development-stage company.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A due to the company's lack of positive earnings, implying that traditional earnings-based valuation multiples are not applicable and that the market is pricing the stock based on future potential rather than historical profitability. The price-to-book ratio is 0.39, indicating that the market values the company at less than one-third of its book value, which often suggests a deep discount or significant uncertainty regarding the recoverable value of its intangible assets. When examining alternative valuation metrics, the price-to-sales ratio sits at 1.57 while the EV/EBITDA is -1317.14, suggesting that investors are pricing the stock based on revenue multiples given the inability to utilize EBITDA-based comparisons in the context of negative earnings. The stock has experienced significant volatility, with a 52-week high of $6.18 and a 52-week low of $0.55, meaning the current trading price fluctuates within a range that reflects extreme market sentiment shifts typical of small-cap biotech stocks. With a beta of 1.99, the stock exhibits price volatility nearly twice that of the broader market, meaning it is highly sensitive to market movements and likely to experience amplified swings during periods of market stress or sector-specific news.
Growth & Income
Revenue growth year-over-year is 30.6%, while earnings growth is listed as N/A, indicating that the company is expanding its top line rapidly but has not yet achieved consistent profitability to calculate meaningful earnings growth rates. This divergence implies that while the company is successfully increasing its sales volume or market penetration, the cost structure remains rigid enough to prevent proportional earnings improvement, a typical pattern in the growth phase of a biopharmaceutical company. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which means it reinvests all available cash flow back into research, development, and operational scaling rather than distributing returns to shareholders. The overall growth and income profile characterizes Scinai as a pure-play growth vehicle with zero current income generation, where value accrual is entirely dependent on the successful commercialization of its nanoAbs technology and the eventual transition from cash burn to positive cash flow.